All consecutive patients treated at the outpatient department of the “Franz Tappeiner” Hospital Merano, from 15 March to 26 May 2020 were included in this retrospective study. Specific infection prevention and control measures were maintained by the hospital as well as our clinic as described previously [14 (link)]. Universal baseline testing for SARS-CoV‑2 RNA was performed using a real-time polymerase chain reaction (RT-PCR) on respiratory samples obtained from nasopharyngeal swabs of patients and all healthcare workers. Furthermore, from 22 June to 17 July 2020 a total of 250 consecutive cancer patients who underwent SARS-CoV‑2 PCR baseline testing as well as the entire healthcare team were tested for the presence of IgG antibodies against SARS-CoV‑2 in venous blood samples. Serologic testing was performed using the commercially available Abbott Architect SARS-CoV‑2 IgG assay to detect immunoglobulin class G (IgG) antibodies to the nucleocapsid protein of SARS-CoV‑2 (Abbott Diagnostics, Chicago, Ill, USA). Sensitivity and specificity for the Abbott Architect SARS-CoV‑2 IgG assay were found to be 100% and 99.6%, respectively [15 (link)]. The study was approved by the local ethics committee of the “Südtiroler Sanitätsbetrieb” (protocol number 35-2020).